Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis.
暂无分享,去创建一个
Courtney Crim | Edwin K Silverman | Ruth Tal-Singer | Bruno Delafont | Emiel F M Wouters | Per Bakke | L. Edwards | E. Silverman | B. Celli | J. Vestbo | P. Bakke | D. Lomas | B. Miller | A. Agustí | E. Wouters | H. Coxson | W. MacNee | J. Yates | S. Rennard | R. Tal-Singer | P. Calverley | C. Crim | B. Delafont | N. Locantore | Peter M A Calverley | Stephen I Rennard | Jørgen Vestbo | David A Lomas | Harvey Coxson | Alvar Agustí | Lisa D Edwards | William MacNee | Bruce E Miller | Julie C Yates | Nicholas Locantore | Bartolomé Celli | Ignacio Coca | Ignacio Coca | W. Macnee
[1] Edwin K Silverman,et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. , 2010, American journal of respiratory and critical care medicine.
[2] S. Sahn,et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. , 2011, American journal of respiratory and critical care medicine.
[3] L. Edwards,et al. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. , 2013, American journal of respiratory and critical care medicine.
[4] Gianna Camiciottoli,et al. Identification of a predominant COPD phenotype in clinical practice. , 2008, Respiratory medicine.
[5] D. Caillaud,et al. Clinical COPD phenotypes identified by cluster analysis: validation with mortality , 2012, European Respiratory Journal.
[6] T. W. van der Mark,et al. Relation of lung function, maximal inspiratory pressure, dyspnoea, and quality of life with exercise capacity in patients with chronic obstructive pulmonary disease. , 1994, Thorax.
[7] Courtney Crim,et al. Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.
[8] M. Krane,et al. Surfactant protein D in serum from patients with allergic bronchopulmonary aspergillosis , 2003, European Respiratory Journal.
[9] J. Wedzicha,et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.
[10] D. Sin,et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.
[11] K. Wasserman,et al. The body weight-walking distance product as related to lung function, anaerobic threshold and peak VO2 in COPD patients. , 2001, Respiratory medicine.
[12] W. MacNee,et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) , 2008, European Respiratory Journal.
[13] Thierry Troosters,et al. Two Distinct Chronic Obstructive Pulmonary Disease (COPD) Phenotypes Are Associated with High Risk of Mortality , 2012, PloS one.
[14] Josep Roca,et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes , 2010, Thorax.
[15] D. Caillaud,et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses , 2010, European Respiratory Journal.
[16] Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials , 2012, Circulation.
[17] N. Laird,et al. Cluster analysis in severe emphysema subjects using phenotype and genotype data: an exploratory investigation , 2010, Respiratory research.
[18] J. Casillas,et al. DETERMINING THE MINIMAL CLINICALLY IMPORTANT 1 DIFFERENCE FOR THE SIX-MINUTE WALK TEST AND THE 2002 METER FAST WALK TEST DURING CARDIAC REHABILITATION 3 PROGRAM IN CORONARY ARTERY DISEASE PATIENTS AFTER 4 ACUTE CORONARY SYNDROME , 2017 .
[19] Yasutaka Nakano,et al. Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.
[20] S. Rennard,et al. Chronic Bronchitis and Emphysema , 2010 .
[21] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[22] B. Everitt,et al. Cluster Analysis: Everitt/Cluster Analysis , 2011 .
[23] Martijn A Spruit,et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.
[24] Edwin K Silverman,et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort , 2010, Respiratory research.
[25] S. Horvath,et al. Unsupervised Learning With Random Forest Predictors , 2006 .
[26] L. Edwards,et al. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort , 2011, Respiratory research.
[27] P. Jones,et al. Issues concerning health-related quality of life in COPD. , 1995, Chest.
[28] Courtney Crim,et al. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. , 2013, The Lancet. Respiratory medicine.
[29] A. Holland,et al. The return of the minimum clinically important difference for 6-minute-walk distance in chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.
[30] Stephanie A. Santorico,et al. Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema , 2014, Thorax.